Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GM-CSF and Rituximab Post-ASCT for Follicular Lymphoma
NCT00521014Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Oct 2007
- Primary completion
- Jul 2013
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sargramostim and rituximab in follicular lymphoma (FL), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Progression-free Survival Rate at 2 years. Started Oct 2007; status: completed.
02
Drugs
sargramostimrituximab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT00521014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00521014.